NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Onco-Innovations Private Placement FAQ
Onco-Innovations announced a CAD$5 million private placement with institutional investors to fund its ONC010 program and SynoGraph platform. The offering involves 6,764,070 units at CAD$0.7392 per unit, expected to close around July 15, 2026.
Onco-Innovations Limited announced a term sheet for a non-brokered private placement of approximately CAD$5 million with institutional investors.
The offering consists of 6,764,070 units at CAD$0.7392 per unit, each unit comprising one common share and one common share purchase warrant.
The closing is expected on or about July 15, 2026, subject to customary conditions and regulatory approvals.
Proceeds will support the development of the ONC010 program (manufacturing and preclinical testing), advancement of the SynoGraph platform, and general working capital.
The investors are arm's-length institutional investors.
The economic interest will be determined through 18 monthly settlement tranches based on the future trading price of its shares, with additional details upon closing.
The full press release is available at https://ibn.fm/y3hsM.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology, with a mission to pursue prevention and treatment through innovative solutions. It holds an exclusive worldwide license to patented technology targeting solid tumours.